Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2011-03-01
2011-03-01
Anderson, Rebecca L (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C514S262100
Reexamination Certificate
active
07897762
ABSTRACT:
The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
REFERENCES:
patent: 6150373 (2000-11-01), Harris et al.
patent: 7112676 (2006-09-01), Dermatakis et al.
patent: 2004/0019210 (2004-01-01), Chivikas Connolly et al.
patent: 2005/0222177 (2005-10-01), Sim et al.
patent: 2006/0004011 (2006-01-01), Ladouceur et al.
patent: 2008/0114006 (2008-05-01), Flynn et al.
patent: WO 99/32111 (1999-07-01), None
patent: WO 99/32455 (1999-07-01), None
patent: WO 01/19828 (2001-03-01), None
patent: WO 03/068223 (2002-08-01), None
patent: WO 2004/061084 (2004-07-01), None
patent: WO 2006/071940 (2006-07-01), None
patent: WO 2006/081034 (2006-08-01), None
patent: WO 2008/051757 (2008-05-01), None
Peyssonnaux, C. et al, “The Raf/MEK/ERK pathway: new concepts of activation,”Biol. Cell(2001) 93: 53-62.
Bolton et al, “Chapter 17.RasOncogene Directed Approaches in Cancer Chemotherapy,”Ann. Rep. Med. Chem.(1994) 29: 165-174.
Magnuson et al, “The Raf-1 serine/threonine protein kinase,”Seminars in Cancer Biology. (1994) 5: 247-253.
Avruch, J. et al., “Ras Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade,”Recent Prog. Horm. Res.(2001) 56: 127-155.
Kolch, W., “Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions,”Biochem. J.(2000) 351: 289-305.
Davies, H. et al, “Mutations of the BRAF gene in human cancer,”Nature(Jun. 2002) 417: 949-954.
Lowinger et al, “Design and Discovery of Small Molecules Targeting Raf-1 Kinase,”Current Pharmaceutical Design(2002) 8: 2269-2278.
Dumas, J. et al, “Recent developments in the discovery of protein kinase inhibitors from the urea class,”Current Opinion in Drug Discovery&Development(2004) 7 (5): 600-616.
Wan, P.T.C. et al, “Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF,”Cell(Mar. 2004) 116: 855-867.
Huse, M. et al, “The Conformational Plasticity of Protein Kinases,”Cell(May 2002) 109: 275-282.
Ettmayer et al, “Lessons Learned from Marketed and Investigational Prodrugs,”J. Med. Chem(May 2004) 47 (10): 2393-2404.
Lorenzi et al, “Amino Acid Ester Prodrugs of 2-Bromo-5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole Enhance Metabolic Stability in Vitro and In Vivo,”J. Pharm. Exp. Therpeutics(2005) 314 (2): 883-890.
Chan et al, “Copper promoted C-N and C-O bond dross-coupling with phenyl and pyridylboronates,”Tetrahedron Lett.(2003) 44: 3863-3865.
Chan et al, “New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate,”Tetrahedron Lett.(1998) 39: 2933-2936.
Chan, D. M. T., “Promotion of Reaction of N-H Bonds with Triatylbismuth and Cupric Acetate,”Tetrahedron Lett.(1996) 37 (50): 9013-9016.
Seto, et al, “2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido [4, 5-b] [1,5]oxazocin-5-one as a structurally new NK1antagonist,”Biorg. Med. Chem. Lett.(2005) 15: 1485-1488.
Pierrat et al, “Solid Phase Synthesis of Pyridine-Based Derivatives from a 2-Chloro-5-Bromopyridine Scaffold,”J. Comb. Chem.(2005) 7 (6): 879-886.
Kroon et al, “Deazapurine derivatives XV. Syntheses of some mono- and difluoroimidazo[4,5-b]- and -4,5-clpyridines,”Recueil des Travaux Chimiques des Pays-Bas(Jun. 1976) 95: 127-129.
O'Brien, et al, “Pyrimidines. XVI. 2,4,5-Triaminopyrimidines and Related Compounds,”J. Med Chem.(Jan. 1966) 9:121-126.
Schindler, et al, “Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase,”Science(Sep. 2000) 289: 1938-1942.
Flynn Daniel L.
Kaufman Michael D.
Patt William C.
Petillo Peter A.
Anderson Rebecca L
Deciphera Pharmaceuticals LLC
Sales James J.
Shterengarts Samantha L
LandOfFree
Kinase inhibitors useful for the treatment of proliferative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinase inhibitors useful for the treatment of proliferative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors useful for the treatment of proliferative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2641131